Revolution Medicines counsel sells 56K shares
Revolution Medicines, Inc. (RVMD) reported that its General Counsel, Jeff Cislini, exercised stock options and sold common shares on August 21, 2026 under a Rule 10b5-1 trading plan adopted on May 22, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Revolution Medicines, Inc. (RVMD) reported that its General Counsel, Jeff Cislini, exercised stock options and sold common shares on August 21, 2026 under a Rule 10b5-1 trading plan adopted on May 22, 2026. He exercised options for 56,280 shares of common stock at exercise prices of $18.56 and $21.61 per share and sold an aggregate of 56,894 shares of common stock in multiple trades at weighted average prices ranging from about $206.76 to $212.74 per share. Cislini’s holdings include 43,514 restricted stock units that remain outstanding.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
10 txns
Insider
Cislini Jeff
Role
General Counsel
Sold
56,894 shs ($11.90M)
Approx. gross sale proceeds
$11.90M
Approx. exercise cost
$1.13M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1 | 29,680 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F1, F9 | 26,600 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 29,680 | $18.56 | $551K |
| Exercise | Common Stock F1, F2 | 26,600 | $21.61 | $575K |
| Sale | Common Stock F1, F3, F2 | 3,400 | $207.2363 | $705K |
| Sale | Common Stock F1, F4 | 17,323 | $208.3688 | $3.61M |
| Sale | Common Stock F1, F5, F2 | 25,817 | $209.2497 | $5.40M |
| Sale | Common Stock F1, F6, F2 | 2,540 | $210.2647 | $534K |
| Sale | Common Stock F1, F7, F2 | 4,500 | $211.3417 | $951K |
| Sale | Common Stock F1, F8, F2 | 3,314 | $212.0583 | $703K |
Holdings After Transaction:
Stock Option (Right to Buy) — 3,500 contracts (Direct);
Common Stock — 55,907 shares (Direct)
Footnotes (9)
- F1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026.
- F2. Includes 43,514 restricted stock units.
- F3. This transaction was executed in multiple trades in prices ranging from $206.76 to $207.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4. This transaction was executed in multiple trades in prices ranging from $207.765 to $208.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F5. This transaction was executed in multiple trades in prices ranging from $208.77 to $209.61, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F6. This transaction was executed in multiple trades in prices ranging from $209.77 to $210.72, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F7. This transaction was executed in multiple trades in prices ranging from $210.77 to $211.76, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F8. This transaction was executed in multiple trades in prices ranging from $211.77 to $212.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F9. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from September 1, 2022 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Key Figures
Options exercised (first grant): 29,680 shares
Exercise price (first grant): $18.56 per share
Options exercised (second grant): 26,600 shares
+5 more
8 metrics
Options exercised (first grant)
29,680 shares
Stock options exercised into RVMD common stock at $18.56 per share on August 21, 2026
Exercise price (first grant)
$18.56 per share
Conversion or exercise price for 29,680 options into RVMD common stock
Options exercised (second grant)
26,600 shares
Stock options exercised into RVMD common stock at $21.61 per share on August 21, 2026
Exercise price (second grant)
$21.61 per share
Conversion or exercise price for 26,600 options into RVMD common stock
Total shares sold
56,894 shares
Aggregate RVMD common shares sold across six sale transactions on August 21, 2026
Sale price range (example footnote)
$206.76–$207.75 per share
Price range for one sale tranche where the reported price is a weighted average
Restricted stock units included in holdings
43,514 RSUs
Number of restricted stock units included in Cislini’s reported RVMD equity holdings
Vesting schedule for option grant
1/48th monthly from September 1, 2022 over 4 years
Monthly vesting of the option expiring August 31, 2032, subject to continued service
Key Terms
Rule 10b5-1 trading plan, restricted stock units, weighted average sale price, Vesting Commencement Date
4 terms
Rule 10b5-1 trading plan regulatory
"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units financial
"Includes 43,514 restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average sale price financial
"The price reported in Column 4 above reflects the weighted average sale price."
Vesting Commencement Date financial
"measured from September 1, 2022 (the "Vesting Commencement Date")"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did RVMD executive Jeff Cislini report in this Form 4?
Jeff Cislini, General Counsel of RVMD, reported exercising options for 56,280 shares of common stock and selling 56,894 shares on August 21, 2026. The transactions were made under a Rule 10b5-1 trading plan adopted on May 22, 2026.
How many Revolution Medicines (RVMD) options did Jeff Cislini exercise and at what prices?
Jeff Cislini exercised 29,680 options at an exercise price of $18.56 per share and 26,600 options at an exercise price of $21.61 per share, for a total of 56,280 shares of RVMD common stock acquired through option exercises.
Were Jeff Cislini’s RVMD trades made under a Rule 10b5-1 plan?
Yes. A footnote states that the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Jeff Cislini on May 22, 2026, and the Rule 10b5-1 checkbox is affirmed.
What restricted stock units does Jeff Cislini hold at Revolution Medicines (RVMD)?
A footnote explains that his reported holdings include 43,514 restricted stock units. These RSUs represent additional rights to receive RVMD common shares, separate from the options exercised and shares sold in the reported transactions.
What is the vesting schedule for one of Jeff Cislini’s RVMD option grants?
For the option with a $21.61 exercise price, a footnote states that 1/48th of the shares vest on each monthly anniversary of September 1, 2022, so 100% will be fully vested and exercisable by the fourth anniversary, subject to continued service.
AI-generated analysis. How Rhea-AI works. Not financial advice.
